285 related articles for article (PubMed ID: 31468739)
1. Serum phosphatidylserine-specific phospholipase A
Sawada T; Kurano M; Shirai H; Iwasaki Y; Tahara K; Hayashi H; Igarashi K; Fujio K; Aoki J; Yatomi Y
Int J Rheum Dis; 2019 Nov; 22(11):2059-2066. PubMed ID: 31468739
[TBL] [Abstract][Full Text] [Related]
2. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M
Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346
[TBL] [Abstract][Full Text] [Related]
3. Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity.
Sellam J; Proulle V; Jüngel A; Ittah M; Miceli Richard C; Gottenberg JE; Toti F; Benessiano J; Gay S; Freyssinet JM; Mariette X
Arthritis Res Ther; 2009; 11(5):R156. PubMed ID: 19832990
[TBL] [Abstract][Full Text] [Related]
4. Elevated phosphatidylserine-specific phospholipase A1 level in hyperthyroidism.
Nakawatari K; Kurano M; Araki O; Nishikawa M; Shimamoto S; Igarashi K; Aoki J; Murakami M; Yatomi Y
Clin Chim Acta; 2020 Apr; 503():99-106. PubMed ID: 31978406
[TBL] [Abstract][Full Text] [Related]
5. Higher serum levels of autotaxin and phosphatidylserine-specific phospholipase A
Iwata Y; Kitajima S; Yamahana J; Shimomura S; Yoneda-Nakagawa S; Sakai N; Furuichi K; Ogura H; Sato K; Toyama T; Yamamura Y; Miyagawa T; Hara A; Shimizu M; Ohkawa R; Kurano M; Yatomi Y; Wada T
Int J Rheum Dis; 2021 Feb; 24(2):231-239. PubMed ID: 33314787
[TBL] [Abstract][Full Text] [Related]
6. Serum anti-lipocalin 2 IgG is a novel biomarker in the diagnosis of systemic lupus erythematosus.
Li YN; Hu FL; Dai YJ; Li R; Ma XX; Du Y; Feng M; Jia Y; Zhang CF; Zhu L; Ascherman DP; Li ZG
Lupus; 2014 Aug; 23(9):868-75. PubMed ID: 24704774
[TBL] [Abstract][Full Text] [Related]
7. Association between serum autotaxin or phosphatidylserine-specific phospholipase A1 levels and melanoma.
Kurano M; Miyagaki T; Miyagawa T; Igarashi K; Shimamoto S; Ikeda H; Aoki J; Sato S; Yatomi Y
J Dermatol; 2018 May; 45(5):571-579. PubMed ID: 29500864
[TBL] [Abstract][Full Text] [Related]
8. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.
Závada J; Uher M; Svobodová R; Olejárová M; Hušáková M; Ciferská H; Hulejová H; Tomčík M; Šenolt L; Vencovský J
Arthritis Res Ther; 2015 Nov; 17():341. PubMed ID: 26608564
[TBL] [Abstract][Full Text] [Related]
9. Hematocrit Level could Reflect Inflammatory Response and Disease Activity in Patients with Systemic Lupus Erythematosus.
Yang M; Ma N; Fu H; Wei T; Tang Q; Qin B; Yang Z; Zhong R
Clin Lab; 2015; 61(7):801-7. PubMed ID: 26299080
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus.
Schaper F; de Leeuw K; Horst G; Maas F; Bootsma H; Heeringa P; Limburg PC; Westra J
Clin Exp Immunol; 2017 Jun; 188(3):412-419. PubMed ID: 28245520
[TBL] [Abstract][Full Text] [Related]
11. Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study.
Fayed A; El Menyawi MM; Ghanema M; Shaker O; Elgohary R
Reumatismo; 2020 Nov; 72(3):145-153. PubMed ID: 33213127
[TBL] [Abstract][Full Text] [Related]
12. Serum Interleukin-26 Is a New Biomarker for Disease Activity Assessment in Systemic Lupus Erythematosus.
Brilland B; Bach-Bunner M; Gomes CN; Larochette V; Foucher E; Plaisance M; Saulnier P; Costedoat-Chalumeau N; Ghillani P; Belizna C; Delneste Y; Augusto JF; Jeannin P
Front Immunol; 2021; 12():663192. PubMed ID: 34054830
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum interleukin-34 level in juvenile systemic lupus erythematosus and disease activity.
El-Banna HS; El Khouly RM; Gado SE
Clin Rheumatol; 2020 May; 39(5):1627-1632. PubMed ID: 31907692
[TBL] [Abstract][Full Text] [Related]
14. Peripheral CD24hi CD27+ CD19+ B cells subset as a potential biomarker in naïve systemic lupus erythematosus.
Jin L; Weiqian C; Lihuan Y
Int J Rheum Dis; 2013 Dec; 16(6):698-708. PubMed ID: 24286662
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Serum β2-microglobulin in Egyptian Patients with Systemic Lupus Erythematosus.
Abd-Elbaky NM; Albeltagy ES; Hammour AE; Ibrahim AS
Egypt J Immunol; 2019 Jul; 26(2):143-153. PubMed ID: 31926503
[TBL] [Abstract][Full Text] [Related]
16. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
17. Decreased serum thrombospondin-1 and elevation of its autoantibody are associated with multiple exacerbated clinical manifestations in systemic lupus erythematosus.
Meng Y; Zhang M; Zhao X; Cheng Y; Jia R; Wang Y; Sun X
Clin Rheumatol; 2018 Oct; 37(10):2707-2714. PubMed ID: 29998369
[TBL] [Abstract][Full Text] [Related]
18. PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus.
Li H; Meng D; Jia J; Wei H
Lipids Health Dis; 2021 Aug; 20(1):95. PubMed ID: 34461924
[TBL] [Abstract][Full Text] [Related]
19. Serum leucine-rich α2-glycoprotein is elevated in patients with systemic lupus erythematosus and correlates with disease activity.
Ahn SS; Park Y; Jung SM; Song JJ; Park YB; Lee SW
Clin Chim Acta; 2018 Nov; 486():253-258. PubMed ID: 30118672
[TBL] [Abstract][Full Text] [Related]
20. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
